Sökning: onr:"swepub:oai:DiVA.org:umu-154049" >
No association betw...
-
Frisk, GabriellaKarolinska Institutet
(författare)
No association between low-dose aspirin use and breast cancer outcomes overall : a Swedish population-based study
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
2018-11-20
-
BioMed Central,2018
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-154049
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-154049URI
-
https://doi.org/10.1186/s13058-018-1065-0DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:139700424URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Results from previous studies indicate that use of low-dose aspirin may improve breast cancer prognosis. We evaluated aspirin use and breast cancer outcomes in relation to clinical characteristics as well as dose and duration of aspirin use.Methods: We used information from the Regional Breast Cancer Quality-of-Care Registries in three Swedish regions to identify 21,414 women diagnosed with a first stage I-III breast cancer between 1 April 2006 and 31 December 2012. The cohort was further linked to nationwide registers to retrieve information about dispensing low-dose aspirin before and after breast cancer diagnosis, comorbidity and causes of death. In a separate analysis, we investigated time to breast cancer death among 621 women with stage IV disease at diagnosis. Associations were evaluated using a multivariable Cox proportional hazards model.Results: Among women with stage I-III breast cancer, 2660 (12.4%) used low-dose aspirin shortly before breast cancer diagnosis and 4091 (19.1%) were users during follow-up. Women were followed for a median of 3.8years after diagnosis. There was no association between aspirin use and breast cancer-specific death in multivariable analyses (use before diagnosis: hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.77-1.12; use after diagnosis: HR 1.00, 95% CI 0.74-1.37). Similarly, aspirin use was not associated with risk of first recurrence/metastases in a subgroup of stage I-III breast cancer patients (HR 0.97, 95% CI 0.86-1.10). However, in analyses stratified by stage, an inverse association between low-dose aspirin use after diagnosis and breast cancer death was found for women with stage I tumors (HR 0.53, 95% CI 0.29-0.96). Among women with stage IV disease at diagnosis, aspirin use was not associated with time to breast cancer death (HR 0.91, 95% CI 0.67-1.23).Conclusion: In this large population-based cohort study there was no evidence that low-dose aspirin use before or after breast cancer diagnosis is associated with a reduced risk of adverse outcomes overall in breast cancer. However, a potential benefit was noted among women with stage I tumors, warranting further investigation.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Ekberg, SaraKarolinska Institutet
(författare)
-
Lidbrink, Elisabet
(författare)
-
Eloranta, SandraKarolinska Institutet
(författare)
-
Sund, MalinUmeå universitet,Kirurgi(Swepub:umu)masu0021
(författare)
-
Fredriksson, IrmaKarolinska Institutet
(författare)
-
Lambe, MatsKarolinska Institutet
(författare)
-
Smedby, Karin E.Karolinska Institutet
(författare)
-
Karolinska InstitutetKirurgi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Breast Cancer Research: BioMed Central201465-54111465-542X
Internetlänk
Hitta via bibliotek
Till lärosätets databas